Company news

Palisade Bio, Inc. news in 2024

Palisade Bio, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

December 16, 2024

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

December 11, 2024

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

December 2, 2024

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

November 20, 2024

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

November 11, 2024

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

November 6, 2024

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

October 30, 2024

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting

October 14, 2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

October 9, 2024

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

September 24, 2024

Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies

September 15, 2024

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

September 4, 2024

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

August 12, 2024

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

August 7, 2024

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

July 28, 2024

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

July 18, 2024

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

July 10, 2024

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

June 20, 2024

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

June 10, 2024

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

May 20, 2024

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Palisade Bio Appoints Margery Fischbein to its Board of Directors

May 6, 2024

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

May 1, 2024

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

April 30, 2024

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

April 22, 2024

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

April 15, 2024

Palisade Bio Announces 1-for-15 Reverse Stock Split

April 2, 2024

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

March 26, 2024

Palisade Bio Provides Corporate Update and Reiterates Guidance

February 12, 2024

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

February 7, 2024

Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million

January 29, 2024

Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress

January 28, 2024

Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress

January 8, 2024

Decks in 2024